BLU.TO

BELLUS Health Inc. [BLU.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BLU.TO Stock Summary

In the News

BLU.TO Financial details

Company Rating
-
Market Cap
2.47B
Income
-86.79M
Revenue
15K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
08 Aug 2023
P/E
-21.24
Forward P/E
-
PEG
11.95
P/S
123141.05
P/B
5
P/C
-
P/FCF
-20.7
Quick Ratio
32.13
Current Ratio
33.42
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.74
EPS next Y
-
EPS next Q
-
EPS this Y
-26.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
26.97%
Revenue last 5Y
-9.04%
Revenue Q/Q
-25%
EPS Q/Q
25%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-24%
ROC
-0.24%
Gross Margin
100%
Oper. Margin
-602047%
Profit Margin
-578587%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.58-19.9
52W High
+2.53%
52W Low
+143.5%
RSI
-
Rel Volume
0.41
Avg Volume
69.41K
Volume
28.67K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-0.1%
-
-
-
-
Beta
-0.27898
-
-
Volatility
0.01%, 0.01%
Prev Close
0%
Price
19.48
Change
-0.15%

Something similar

Top by Market Cap
V
1YD.DE
NVDA
AVGO
FB2A.DE
Same Sector
AVHHL
HCAT
SN.L
3183.T
NVS
Check Those
AMP
CGO.L
0601.HK
603032.SS
AMLM
Similar Market Cap
601086.SS
ZPAB.DE
TCLB.TO
BVN
0596.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 69.41K
  • Market Capitalization 2.47B
  • Employee 74
  • CEO Mr. Roberto Francesco Bellini
  • Headquarters Laval,QC,CA
  • IPO Date 2000-06-22
  • Website https://www.bellushealth.com

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.